1990 Volume 51 Issue 7 Pages 1380-1388
In order to study an availability of a new tumor marker BCA225, serum concentration of BCA225 was measured in 514 healthy individuals, and the baseline value was established from the resuruts. In 58 cases of primary breast carcinoma and 20 of recurrent breast carcinoma, BCA225, CEA, and CA15-3 were compared for the positive rate. Positive rate for BCA225 increased with a progression of the disease which was as high as 70% for recurrent breast carcinoma, Excepting breast carcinoma, BCA225 shoed the positive rate of 10.0% for various types of malignant diseases, 0.0% for benign breast tumors of the mammary gland, or 5.3% for benign breast tumors at othert sites, indicating that BCA225 was specific for breast carcinoma. In a combination assay using BCA225 and/or CEA, the highest positive rate was obtained in both primary and recurrent breast carcinoma in respect to the rerationship with the hormone receptors, the patient group which was negative for both ER and PR showed a high level of BCA225. Histologically the highest positive rate was found in solid carcinomas. A correlation between BCA225 and CA15-3 was observed, in which the condition of these antigens was discussed.
